SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): MAY 28, 1998

                           COPLEY PHARMACEUTICAL, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                    DELAWARE
         (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

                      0-20126                     04-2514637

           (COMMISSION FILE NUMBER)   (IRS EMPLOYER IDENTIFICATION NO.)

                   25 JOHN ROAD
               CANTON, MASSACHUSETTS                   02021
      (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)       (ZIP CODE)

                                 (781) 821-6111
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)


<PAGE>




ITEM 5            OTHER EVENTS

The Annual Meeting of Shareholders of Copley Pharmaceutical,  Inc. (NASDAQ:CPLY)
was held on May 28, 1998.  Shareholders  elected Robert P. Cook, Jane C.I. Hirsh
and David A. Jenkins as  Directors,  each to serve a three year term.  KPMG Peat
Marwick LLP was ratified as the Company's  auditors for the year ending December
31, 1998.

Following the Annual Meeting of  Shareholders,  the Board of Directors of Copley
met  and  decided  not to  renew  its  previously  announced  retention  of CIBC
Oppenheimer & Co. While continuing to review strategic  alternatives,  the Board
intends to concentrate its immediate efforts on hiring a Chief Executive Officer
for Copley.

The Board  elected  David A.  Jenkins,  President  of  Hoechst  Corporation,  as
Chairman.  Mr. Jenkins replaces Kenneth N. Larsen,  who chose not to continue as
Chairman and remains a member of the Board.

The Board also elected Daniel M.P. Caron as the Company's Vice President,  Chief
Financial  Officer and  Treasurer  effective  June 15,  1998,  replacing  Ken E.
Starkweather, the current holder of these titles, who will be leaving to begin a
long-planned  retirement.  Mr. Caron has been Copley's Corporate  Controller for
nearly six years; prior to joining Copley, Mr. Caron was Chief Financial Officer
at Rosecraft, Inc. and a Certified Public Accountant for Coopers and Lybrand.

Copley   Pharmaceutical,   Inc.  headquartered  in  Canton,  MA,  is  a  leading
manufacturer  and  marketer of a broad range of  multi-source  prescription  and
over-the-counter  pharmaceuticals  in a variety  of dosage  forms.  The  Company
markets its products to  distributors,  retail chains,  wholesalers,  hospitals,
government agencies and managed health care entities.

Forward-looking  statements  (statements which are not historical facts) in this
release  are  made  pursuant  to the  safe  harbor  provisions  of  the  Private
Securities  Litigation  Reform Act of 1995.  Investors  are  cautioned  that all
forward-looking  statements  involve risks and  uncertainties,  including  those
risks and  uncertainties  detailed in the Company's  filings with the Securities
and Exchange Commission, copies of which are available from the Company.


<PAGE>
                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


           SIGNATURE                              TITLE                 DATE

 /s/  Ken E. Starkweather      Vice President-Finance, Chief        June 8, 1998
---------------------------    Financial Officer and Treasurer
      Ken E. Starkweather      (principal financial and principal
                                accounting officer)
[{"type": "8-K", "sequence": "1", "description": "RESULTS OF ANNUAL MEETING", "secsgml_size_bytes": 3886}]
{"company-data": {"conformed-name": "COPLEY PHARMACEUTICAL INC", "cik": "0000829987", "assigned-sic": "2834", "irs-number": "042514637", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-20126", "film-number": "98644084"}, "business-address": {"street1": "25 JOHN RD ST 13TH FL", "city": "CANTON", "state": "MA", "zip": "02021", "phone": "6178216111"}, "mail-address": {"street1": "25 JOHN ROAD", "city": "CANTON", "state": "MA", "zip": "02021"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): MAY 28, 1998

                           COPLEY PHARMACEUTICAL, INC.
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

                                    DELAWARE
         (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION)

                      0-20126                     04-2514637

           (COMMISSION FILE NUMBER)   (IRS EMPLOYER IDENTIFICATION NO.)

                   25 JOHN ROAD
               CANTON, MASSACHUSETTS                   02021
      (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)       (ZIP CODE)

                                 (781) 821-6111
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
ITEM 5            OTHER EVENTS

The Annual Meeting of Shareholders of Copley Pharmaceutical,  Inc. (NASDAQ:CPLY)
was held on May 28, 1998.  Shareholders  elected Robert P. Cook, Jane C.I. Hirsh
and David A. Jenkins as  Directors,  each to serve a three year term.  KPMG Peat
Marwick LLP was ratified as the Company's  auditors for the year ending December
31, 1998.

Following the Annual Meeting of  Shareholders,  the Board of Directors of Copley
met  and  decided  not to  renew  its  previously  announced  retention  of CIBC
Oppenheimer & Co. While continuing to review strategic  alternatives,  the Board
intends to concentrate its immediate efforts on hiring a Chief Executive Officer
for Copley.

The Board  elected  David A.  Jenkins,  President  of  Hoechst  Corporation,  as
Chairman.  Mr. Jenkins replaces Kenneth N. Larsen,  who chose not to continue as
Chairman and remains a member of the Board.

The Board also elected Daniel M.P. Caron as the Company's Vice President,  Chief
Financial  Officer and  Treasurer  effective  June 15,  1998,  replacing  Ken E.
Starkweather, the current holder of these titles, who will be leaving to begin a
long-planned  retirement.  Mr. Caron has been Copley's Corporate  Controller for
nearly six years; prior to joining Copley, Mr. Caron was Chief Financial Officer
at Rosecraft, Inc. and a Certified Public Accountant for Coopers and Lybrand.

Copley   Pharmaceutical,   Inc.  headquartered  in  Canton,  MA,  is  a  leading
manufacturer  and  marketer of a broad range of  multi-source  prescription  and
over-the-counter  pharmaceuticals  in a variety  of dosage  forms.  The  Company
markets its products to  distributors,  retail chains,  wholesalers,  hospitals,
government agencies and managed health care entities.

Forward-looking  statements  (statements which are not historical facts) in this
release  are  made  pursuant  to the  safe  harbor  provisions  of  the  Private
Securities  Litigation  Reform Act of 1995.  Investors  are  cautioned  that all
forward-looking  statements  involve risks and  uncertainties,  including  those
risks and  uncertainties  detailed in the Company's  filings with the Securities
and Exchange Commission, copies of which are available from the Company.
SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

           SIGNATURE                              TITLE                 DATE

 /s/  Ken E. Starkweather      Vice President-Finance, Chief        June 8, 1998
---------------------------    Financial Officer and Treasurer
      Ken E. Starkweather      (principal financial and principal
                                accounting officer)